Northwest Biotherapeutics, Inc.
NWBO
$0.23
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -33.50% | 10.25% | -28.47% | -23.42% | -12.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -33.50% | 10.25% | -28.47% | -23.42% | -12.69% |
| Cost of Revenue | 11.47% | 22.51% | 25.81% | 7.40% | 2.55% |
| Gross Profit | -14.00% | -23.11% | -29.88% | -9.73% | -3.57% |
| SG&A Expenses | -2.67% | 11.16% | 11.08% | 6.22% | 2.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.17% | 16.64% | 18.19% | 6.79% | 2.57% |
| Operating Income | -5.17% | -16.79% | -19.82% | -7.87% | -3.05% |
| Income Before Tax | -11.72% | -20.71% | -33.83% | 9.60% | 14.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.72% | -20.71% | -33.83% | 9.60% | 14.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.72% | -20.71% | -33.83% | 9.60% | 14.57% |
| EBIT | -5.17% | -16.79% | -19.82% | -7.87% | -3.05% |
| EBITDA | -5.21% | -17.04% | -19.97% | -7.52% | -2.45% |
| EPS Basic | 2.79% | -6.03% | -18.99% | 17.85% | 21.32% |
| Normalized Basic EPS | 7.61% | -3.45% | -24.03% | 10.05% | 26.04% |
| EPS Diluted | -4.18% | -13.17% | -26.83% | 11.58% | 21.32% |
| Normalized Diluted EPS | 7.61% | -3.45% | -24.03% | 10.05% | 26.04% |
| Average Basic Shares Outstanding | 14.24% | 12.00% | 11.00% | 10.13% | 9.64% |
| Average Diluted Shares Outstanding | 14.24% | 12.00% | 11.00% | 10.13% | 9.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |